Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSP103
- Development stage
- Preclinical
- Lead developer
- Methapharm
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
MSP103 is a respiratory drug candidate currently in development by Methapharm. It is part of the company's specialty respiratory portfolio, which focuses on diagnostic and therapeutic products for lung health, such as bronchoprovocation challenge agents. As of the 2024 pipeline update, the specific active pharmaceutical ingredient and molecular target for MSP103 have not been publicly disclosed. However, the product is scheduled for a target launch in 2024, suggesting it is in the late stages of clinical development or undergoing regulatory review.
Beyond the preview
Go deeper on MSP103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSP103.